AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01570179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ideal BW based sugammadex reversal of moderate block
Description: 2 mg/kg sugammadex (based og ideal body weight)
Study NCT01570179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: real body weight based sugammadex reversal of moderate block
Description: 2 mg/kg sugammadex (based on real BW)
Study NCT01570179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: real body weight based sugammadex reversal of deep block
Description: 4 mg/kg sugammadex (based on real BW)
Study NCT01570179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ideal body weight based sugammadex reversal of deep block
Description: 4 mg/kg sugammadex (based on ideal BW)
Study NCT04690296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cathetherization approach
Description: real time ultrasound guidance versus anatomical landmarks subcalvain vein catheterization
Study NCT06385912 — intervention group
Intervention type: PROCEDURE
Intervention: lymphadenectomy
Description: Systematic pelvic and para-aortic lymphadenectomy during IDS in lymphadenectomy group
Study NCT04159116 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prophylactic suctioning when clinically indicated
Description: Suctioned prophylactically when clinically indicated by copious secretions, coughing, choking or desaturatation
Study NCT04159116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylactic suctioning when clinically indicated
Description: Suctioned prophylactically when clinically indicated by copious secretions, coughing, choking or desaturatation
Study NCT03711019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Description: MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.
Study NCT03711019 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RUL-UB ECT
Description: In the RUL-UB ECT arm treatment, the MECTA spectrum 5000Q or MECTA Sigma machine will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.
Study NCT03711019 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bitemporal ECT
Description: Bitemporal ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Bitemporal ECT will be administered at 1.5 times seizure threshold according to standard clinical practice. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.
Study NCT01243593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block
Description: A block needle will be advanced in a medial to lateral direction until the tip is visualized in the transversus abdominis plane. After negative aspiration 0.4 ml/kg of bupivacaine 0.25% with 1:200 000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
Study NCT01243593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Anesthesia
Description: Local field infiltration with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg before skin incision.
Study NCT03088605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1630 Ophthalmic Solution
Description: Bilateral ocular drug administration
Study NCT03088605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to TOP1630 Ophthalmic Solution
Description: Bilateral ocular drug administration
Study NCT00302237 — intervention group
Intervention type: DEVICE
Intervention: RX ACCULINK, RX ACCUNET Embolic Protection System
Description: 1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
Study NCT02061137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fingolimod (FTY720)
Description: 0.5 or 0.25 mg fingolimod orally daily for each of 6 patients with rett syndrome for 12 months
Study NCT02135640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab 60mg
Description: solution
Study NCT02135640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab 120 mg
Description: solution
Study NCT02135640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: solution
Study NCT03854955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iScribes
Description: Device-based scribing service.
Study NCT04410783 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Nurses and physicians will be engaged regarding the clinical outcome data on the importance of ED-based sedation, and the objectives of the research. Education will include in-services and lectures focused on the importance of sedation protocols on patient outcome. The use of sedation will be evaluated throughout the study in order to better understand providers' perception of and experience with ED-based sedation protocols.
Study NCT01694771 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tiotropium
Description: Marketed dose
Study NCT01694771 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo matching Olodaterol
Description: One dose
Study NCT03072771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: -Blinatumomab is a bispecific T cell engaging antibody
Study NCT03072771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant
Description: -Standard of care
Study NCT03072771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: -Carmustine is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of carmustine.
Study NCT03072771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: -Etoposide is a semi-synthetic podophyllotoxin derivative. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of etoposide.
Study NCT04604262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waterpik
Description: Waterpik dental water jet
Study NCT03582423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: Eight acupoints are chosen: he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
Study NCT03582423 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: electro-acupuncture
Description: Eight acupoints are chosen: he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
Study NCT03072771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: -Cytarabine, commonly known as Ara-C, is a synthetic nucleoside. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of cytarabine.
Study NCT03072771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: -Melphalan is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of melphalan.
Study NCT03072771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draws
Description: -Day +42, Day + 43, Day +56, and Day +100
Study NCT03914508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory + Behavioral Weight Loss
Description: BWL and memory enhancement (M+BWL) will be integrated to capitalize on the strengths of both treatments. All participants will be taught general behavioral weight loss skills including to decrease caloric intake and increase physical activity, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss. The proposed M+BWL program provides memory interventions based on the literature, including eating attentively, memory of previous meal, memory skills for planning, effects of diet on memory and the relationship between memory and satiety. The M+BWL program will also utilize experiential learning during the group program such as practicing memory enhanced skills during eating.
Study NCT04410783 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard post intubation sedation practices
Description: Usual care sedation provide in the ED
Study NCT02859415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mithramycin
Description: Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses; Phase 2: 24 hour intravenous infusion of mithramycin given once every 14 days at MTD established in phase 1
Study NCT03705923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy
Study NCT03939910 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal Nerve Block needle in pre-packaged kits that include both the trumpet and the needle. The needle will limits its depth of penetration to 5 mm beyond the trumpet.
Description: Patients will receive a pudendal nerve block injection on each side as previously described 5-10 minutes before the beginning of surgery. A tubular director that allows 1.0-1.5 cm of a 15-cm-long, 22-gauge needle to protrude beyond its tip will be used to guide the needle into the pudendal trunk at lesser sciatic foramen about 1 cm inferior-medial to attachment of the sacrospinous ligament to the ischial spine. The end of the director will be placed against the vaginal epithelium just beneath the tip of the ischial spine. The needle pushed beyond the tip of the director, and 5 ml of the anaesthetic solution will be injected. The needle advanced 1 cm posterior and lateral, and another 5 mL of the anaesthetic solution will be injected into this region.
Study NCT03939910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pudendal Nerve Block needle in pre-packaged kits that include both the trumpet and the needle. The needle will limits its depth of penetration to 5 mm beyond the trumpet.
Description: Patients will receive a pudendal nerve block injection on each side as previously described 5-10 minutes before the beginning of surgery. A tubular director that allows 1.0-1.5 cm of a 15-cm-long, 22-gauge needle to protrude beyond its tip will be used to guide the needle into the pudendal trunk at lesser sciatic foramen about 1 cm inferior-medial to attachment of the sacrospinous ligament to the ischial spine. The end of the director will be placed against the vaginal epithelium just beneath the tip of the ischial spine. The needle pushed beyond the tip of the director, and 5 ml of the anaesthetic solution will be injected. The needle advanced 1 cm posterior and lateral, and another 5 mL of the anaesthetic solution will be injected into this region.
Study NCT03403244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-MR image fusion-guided PTED
Description: patients diagnosed with lumbar disc herniation undergoing US-MR image fusion-guided PTED
Study NCT03403244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fluoroscopy-guided PTED
Description: patients diagnosed with lumbar disc herniation undergoing fluoroscopy-guided PTED
Study NCT06136338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Women in the experimental group underwent four sessions of mindfulness training. The mindfulness training started at the 28th week of pregnancy for the women, the second training was at the 30th week of pregnancy, the third was at the 32nd week of pregnancy, and the last was at the 34th week of pregnancy, with each session lasting 45 minutes.
Study NCT02526849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Description: Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
Study NCT02526849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Conventional treatment was taken by both of two groups. If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax®, Ipsen, Paris, France). If ineffective, an enema could be used.
Study NCT04507217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab, Carboplatin, Pemetrexed
Description: Tislelizumab: 200mg administered intravenously (IV) on Day 1 of each 21-day cycle~Carboplatin: AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles~Pemetrexed: 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
Study NCT03758677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 30 patients who progressed after EGFR-TKI treatment without T790M mutation will receive apatinib 250mg qd orally combine with chemotherapy , if the patient has a grade 3/4 adverse reaction during such treatment, apatinib should be reduced to 250mg orally once per two days. Chemotherapeutic agents are limited to platinum-based double drugs(Pemetrexed,Gemcitabine,Docetaxel).
Study NCT03721679 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months
Description: Same as above
Study NCT02835352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential oils massages
Study NCT02835352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oil massages
Study NCT00611871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection
Study NCT00611871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection
Study NCT00611871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40mg placebo, followed 2 hrs after with 60mg placebo
Study NCT00366639 — intervention group
Intervention type: OTHER
Intervention: Acute Decompensated Heart Failure
Description: Treatment \& outcomes during hospital admission for Acute DHF
Study NCT02390518 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Patients with 1 to 5 brain metastases will be treated. Patients will be assigned to one of four cohorts based on the size of their brain lesions. For each patient, a single lesion will be treated at experimental dose level, other metastases (if present) will receive standard SRS doses.~Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Cohort 1a and 1a Expansion (starting at Dose Level 3) Diameter: ≤ 10 mm Volume: ≤ 0.5236 cm3 26 Gy 28 Gy 30 Gy n/a Cohort 1b Diameter: 11-20 mm Volume: 0.5237-4.1888 cm3 26 Gy 28 Gy 30 Gy n/a \*Cohort 2 Diameter: 21-30 mm Volume: 4.1889-14.1372 cm3 20 Gy 22 Gy 24 Gy n/a~\*\*Cohort 3 Diameter: 31-40 mm Volume: 14.1373-33.5103 cm3 17 Gy 19 Gy 21 Gy 23 Gy~Dose Escalation A non-standard 5+4 design will be used for the dose escalation. For each cohort, an initial group of 5 patients will be accrued at dose level 1 and receive experimental treatment to one of their lesions.
Study NCT01694771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: One dose
Study NCT01821248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Cisplatin, S-1
Description: Preoperative chemotherapy (GCS) 3 cycles -FDG-PET- surgery~GCS therapy Gemcitabine 1000mg/m2/day1 Cisplatin 25mg/m2/day1 S-1 100mg/body/day1-7
Study NCT01694771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Marketed dose
Study NCT00005596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00005596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT03757195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Augmentation
Description: combination product
Study NCT06241222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Blend Oral Tablet
Description: In our study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery
Study NCT01758601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention with 7 servings oh white fish per week (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain)
Study NCT00005596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: 30 mg/m2 IV Day 1 of weeks 16, 17, and 18. Give Week 16 dose if ANC ≥ 500/μL and platelets ≥ 75,000/μL. Continue to give during Weeks 17 and 18, even in the face of uncomplicated myelosuppression
Study NCT00005596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 6 mg/m2/day divided BID for 7 days during weeks 8 and 17.
Study NCT00005596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 5 mg/m2/dose of leucovorin will be given PO q12h x 2 doses beginning 48 hours after the start of the MTX.
Study NCT00005596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: 50 mg/m2 dose po qhs Weeks 5 through 13 (total 9 wks) and from Week 24 until the end of consolidation. Only hold for uncomplicated myelosuppression, only if IV MTX course is delayed, until ANC > 500/μL and platelets > 75,000/uL
Study NCT00005596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: IV: 1 gm/m2 given as a 200 mg/m2 bolus over 20 min followed by 800 mg/m2 over 23.6 hours given during Weeks 7, 10, 13, 16, 19, and 22.~IT: Doses by age, Weeks 7, 10, 13, 16, 19 and 22.
Study NCT01758601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention with 7 servings oh white fish per week (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain)
Study NCT00005596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: 2,500 IU/m2 will be given IM x 1 on Days 2,3,or 4 of Week 16; > or = 1 day after the IT MTX
Study NCT00005596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: 60 mg/m2 po qhs during Weeks 20 and 21 (total 14 days). Start week 20 when ANC > or = 500/ul and platelets > or = 75,000/uL. Continue to give all 14 doses despite uncomplicated myelosuppression.
Study NCT00005596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.5 mg/m2 IV on Day 1 of Weeks 8, 9, 17 and 18 (max 2 mg)
Study NCT02326688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinematic analysis of trunk compensation
Study NCT04065854 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Assessment, tailored strength and balance exercise programme, activity analysis and risk enablement advice, and assessment for environmental hazards. Tailored adherence support and supervision.